Alexey L. Margolin
Fundador en ALLENA PHARMACEUTICALS, INC. .
Relaciones activas
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Robert Gallotto | M | 59 |
Alnara Pharmaceuticals, Inc.
 Alnara Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alnara Pharmaceuticals, Inc. develops and commercializes protein therapeutics for the treatment of metabolic diseases. It also develops liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT) for the treatment of exocrine pancreatic insufficiency (EPI). The company was founded by Christoph H. Westphal, Richard H. Aldrich and Alexy L. Margolin in 2008 and is headquartered in Boston, MA.
Altus Pharmaceuticals, Inc.
 Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA.
Anagram Therapeutics, Inc.
 Anagram Therapeutics, Inc. Medical/Nursing ServicesHealth Services Anagram Therapeutics, Inc. provides healthcare services. The company is based in Framingham, MA. The CEO of the company is Robert Gallotto. | 13 años |
| Richard Aldrich | M | 69 |
Alnara Pharmaceuticals, Inc.
Alnara Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alnara Pharmaceuticals, Inc. develops and commercializes protein therapeutics for the treatment of metabolic diseases. It also develops liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT) for the treatment of exocrine pancreatic insufficiency (EPI). The company was founded by Christoph H. Westphal, Richard H. Aldrich and Alexy L. Margolin in 2008 and is headquartered in Boston, MA.
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | 16 años |
| James Topper | M | 62 |
Alcresta Therapeutics, Inc.
 Alcresta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Alcresta Therapeutics, Inc. engages in the development of enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. It offers products designed to improve the delivery, digestion, and absorption of long-chain polyunsaturated fatty acids or LCPUFAs. The company was founded by Robert Gallotto and Dr. Alexey L. Margolin in 2011 and is headquartered in Newton, MA. | 13 años |
| Stephen Kraus | M | 47 |
Alcresta Therapeutics, Inc.
Alcresta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Alcresta Therapeutics, Inc. engages in the development of enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. It offers products designed to improve the delivery, digestion, and absorption of long-chain polyunsaturated fatty acids or LCPUFAs. The company was founded by Robert Gallotto and Dr. Alexey L. Margolin in 2011 and is headquartered in Newton, MA. | 8 años |
| Daniel R. Orlando | M | 58 |
Alcresta Therapeutics, Inc.
Alcresta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Alcresta Therapeutics, Inc. engages in the development of enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. It offers products designed to improve the delivery, digestion, and absorption of long-chain polyunsaturated fatty acids or LCPUFAs. The company was founded by Robert Gallotto and Dr. Alexey L. Margolin in 2011 and is headquartered in Newton, MA. | 5 años |
| Ann Miller | M | 66 | 4 años | |
| Mark J. Fitzpatrick | M | 61 | 3 años | |
| Hugh Wight | M | - |
Alnara Pharmaceuticals, Inc.
Alnara Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alnara Pharmaceuticals, Inc. develops and commercializes protein therapeutics for the treatment of metabolic diseases. It also develops liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT) for the treatment of exocrine pancreatic insufficiency (EPI). The company was founded by Christoph H. Westphal, Richard H. Aldrich and Alexy L. Margolin in 2008 and is headquartered in Boston, MA. | 4 años |
| Geoffrey A. Swire | M | - | 6 años | |
| Steve Dubin | M | 70 |
Alcresta Therapeutics, Inc.
Alcresta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Alcresta Therapeutics, Inc. engages in the development of enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. It offers products designed to improve the delivery, digestion, and absorption of long-chain polyunsaturated fatty acids or LCPUFAs. The company was founded by Robert Gallotto and Dr. Alexey L. Margolin in 2011 and is headquartered in Newton, MA. | - |
| Drucy Borowitz | M | - |
Anagram Therapeutics, Inc.
Anagram Therapeutics, Inc. Medical/Nursing ServicesHealth Services Anagram Therapeutics, Inc. provides healthcare services. The company is based in Framingham, MA. The CEO of the company is Robert Gallotto. | - |
| Preston Campbell | M | - |
Anagram Therapeutics, Inc.
Anagram Therapeutics, Inc. Medical/Nursing ServicesHealth Services Anagram Therapeutics, Inc. provides healthcare services. The company is based in Framingham, MA. The CEO of the company is Robert Gallotto. | - |
| Chris Parrish | M | - |
Alcresta Therapeutics, Inc.
Alcresta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Alcresta Therapeutics, Inc. engages in the development of enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. It offers products designed to improve the delivery, digestion, and absorption of long-chain polyunsaturated fatty acids or LCPUFAs. The company was founded by Robert Gallotto and Dr. Alexey L. Margolin in 2011 and is headquartered in Newton, MA. | 3 años |
| Robert K. Coughlin | M | 55 |
Anagram Therapeutics, Inc.
Anagram Therapeutics, Inc. Medical/Nursing ServicesHealth Services Anagram Therapeutics, Inc. provides healthcare services. The company is based in Framingham, MA. The CEO of the company is Robert Gallotto. | - |
| Matthew Foster | M | - | 2 años | |
| Todd Creech | M | 56 |
Alcresta Therapeutics, Inc.
Alcresta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Alcresta Therapeutics, Inc. engages in the development of enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. It offers products designed to improve the delivery, digestion, and absorption of long-chain polyunsaturated fatty acids or LCPUFAs. The company was founded by Robert Gallotto and Dr. Alexey L. Margolin in 2011 and is headquartered in Newton, MA. | 7 años |
| Jeremy David Lack | M | - |
Alcresta Therapeutics, Inc.
Alcresta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Alcresta Therapeutics, Inc. engages in the development of enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. It offers products designed to improve the delivery, digestion, and absorption of long-chain polyunsaturated fatty acids or LCPUFAs. The company was founded by Robert Gallotto and Dr. Alexey L. Margolin in 2011 and is headquartered in Newton, MA. | - |
| Alan Muney | M | 70 |
Alcresta Therapeutics, Inc.
Alcresta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Alcresta Therapeutics, Inc. engages in the development of enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. It offers products designed to improve the delivery, digestion, and absorption of long-chain polyunsaturated fatty acids or LCPUFAs. The company was founded by Robert Gallotto and Dr. Alexey L. Margolin in 2011 and is headquartered in Newton, MA. | 4 años |
| Andrew Miller | M | - |
Anagram Therapeutics, Inc.
Anagram Therapeutics, Inc. Medical/Nursing ServicesHealth Services Anagram Therapeutics, Inc. provides healthcare services. The company is based in Framingham, MA. The CEO of the company is Robert Gallotto. | - |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Louis Brenner | M | 54 | 7 años | |
| Christoph Westphal | M | 56 |
Alnara Pharmaceuticals, Inc.
Alnara Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alnara Pharmaceuticals, Inc. develops and commercializes protein therapeutics for the treatment of metabolic diseases. It also develops liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT) for the treatment of exocrine pancreatic insufficiency (EPI). The company was founded by Christoph H. Westphal, Richard H. Aldrich and Alexy L. Margolin in 2008 and is headquartered in Boston, MA. | - |
| Bruce A. Leicher | M | 68 |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | 2 años |
| Daniel Tassé | M | 64 |
Alcresta Therapeutics, Inc.
Alcresta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Alcresta Therapeutics, Inc. engages in the development of enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. It offers products designed to improve the delivery, digestion, and absorption of long-chain polyunsaturated fatty acids or LCPUFAs. The company was founded by Robert Gallotto and Dr. Alexey L. Margolin in 2011 and is headquartered in Newton, MA. | 2 años |
| Robert Alexander | M | 54 | 6 años | |
| Thomas J. Phair | M | - |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | 3 años |
| Edward Wholihan | M | 64 | 5 años | |
| Anastasios Konidaris | M | 57 |
Alcresta Therapeutics, Inc.
Alcresta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Alcresta Therapeutics, Inc. engages in the development of enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. It offers products designed to improve the delivery, digestion, and absorption of long-chain polyunsaturated fatty acids or LCPUFAs. The company was founded by Robert Gallotto and Dr. Alexey L. Margolin in 2011 and is headquartered in Newton, MA. | 4 años |
| Andrew Hack | M | 50 | 3 años | |
| Robert Tepper | M | 68 | 9 años | |
| Annamaria T. Kausz | M | 60 | - | |
| Axel Bolte | M | 52 | 5 años | |
| Allene Diaz | F | 59 | 3 años | |
| Sheldon Berkle | M | 78 |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | 3 años |
| John Tucker | M | 61 |
Alcresta Therapeutics, Inc.
Alcresta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Alcresta Therapeutics, Inc. engages in the development of enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. It offers products designed to improve the delivery, digestion, and absorption of long-chain polyunsaturated fatty acids or LCPUFAs. The company was founded by Robert Gallotto and Dr. Alexey L. Margolin in 2011 and is headquartered in Newton, MA. | 2 años |
| Jonathan Lieber | M | 54 |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | 7 años |
| Alan Kimura | M | - |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | - |
| Kenneth Attie | M | 67 |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | 2 años |
| Michael Wyzga | M | 69 |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | 5 años |
| David J. Clark | M | 59 | 2 años | |
| Uday Patel | M | - |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | 7 años |
| Thomas Rowland | M | 58 |
Alnara Pharmaceuticals, Inc.
Alnara Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alnara Pharmaceuticals, Inc. develops and commercializes protein therapeutics for the treatment of metabolic diseases. It also develops liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT) for the treatment of exocrine pancreatic insufficiency (EPI). The company was founded by Christoph H. Westphal, Richard H. Aldrich and Alexy L. Margolin in 2008 and is headquartered in Boston, MA. | - |
| Russell Clayton | M | 63 |
Alcresta Therapeutics, Inc.
Alcresta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Alcresta Therapeutics, Inc. engages in the development of enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. It offers products designed to improve the delivery, digestion, and absorption of long-chain polyunsaturated fatty acids or LCPUFAs. The company was founded by Robert Gallotto and Dr. Alexey L. Margolin in 2011 and is headquartered in Newton, MA. | 2 años |
| Janet Giroux | F | - | 3 años | |
| Chris Stevens | M | 65 |
Alnara Pharmaceuticals, Inc.
Alnara Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alnara Pharmaceuticals, Inc. develops and commercializes protein therapeutics for the treatment of metabolic diseases. It also develops liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT) for the treatment of exocrine pancreatic insufficiency (EPI). The company was founded by Christoph H. Westphal, Richard H. Aldrich and Alexy L. Margolin in 2008 and is headquartered in Boston, MA. | 2 años |
| John Gustofson | M | - |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | 4 años |
| Alicja Januszewicz | M | - | - | |
| Garheng Kong | M | 49 |
Alcresta Therapeutics, Inc.
Alcresta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Alcresta Therapeutics, Inc. engages in the development of enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. It offers products designed to improve the delivery, digestion, and absorption of long-chain polyunsaturated fatty acids or LCPUFAs. The company was founded by Robert Gallotto and Dr. Alexey L. Margolin in 2011 and is headquartered in Newton, MA. | 2 años |
| Rebecca Dabora | M | 66 |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | - |
| Lee R. Brettman | M | 77 |
Alnara Pharmaceuticals, Inc.
Alnara Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alnara Pharmaceuticals, Inc. develops and commercializes protein therapeutics for the treatment of metabolic diseases. It also develops liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT) for the treatment of exocrine pancreatic insufficiency (EPI). The company was founded by Christoph H. Westphal, Richard H. Aldrich and Alexy L. Margolin in 2008 and is headquartered in Boston, MA. | - |
| Lynne Brum | F | 60 |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | - |
| Michael Miller | M | 67 | - | |
| Gino Santini | M | 67 | 10 años | |
| Lauren Sabella | F | 63 |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | 2 años |
| Burkhard Blank | M | 69 |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | 3 años |
| Philip Gotwals | M | 61 |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | 3 años |
| Jonathan Leff | M | 55 |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | 4 años |
| Harry Penner | M | 78 |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | 3 años |
| John M. Sorvillo | M | 69 |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | 3 años |
| Richard D. Forrest | M | 75 |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | - |
| Stewart John Hen | M | 57 |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | 4 años |
| Renato Fuchs | M | 80 |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | 1 años |
| Martin D. Williams | M | 58 |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | 1 años |
| John P. Richard | M | 66 |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | 8 años |
| Richard D. Katz | M | 60 | 1 años | |
| Don G. Burstyn | M | - |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | - |
| Ashley L. Dombkowski | M | - |
Alnara Pharmaceuticals, Inc.
Alnara Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alnara Pharmaceuticals, Inc. develops and commercializes protein therapeutics for the treatment of metabolic diseases. It also develops liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT) for the treatment of exocrine pancreatic insufficiency (EPI). The company was founded by Christoph H. Westphal, Richard H. Aldrich and Alexy L. Margolin in 2008 and is headquartered in Boston, MA. | - |
| Kevin Brennan | M | 54 | 3 años |
Estadísticas
| País | Relaciones | % del total |
|---|---|---|
| Estados Unidos | 67 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Alexey L. Margolin
- Red Personal
